Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Original Paper
  • Published:

Stage-specific changes in SR splicing factors and alternative splicing in mammary tumorigenesis

Abstract

Using a mouse model of mammary gland development and tumorigenesis we examined changes in both alternative splicing and splicing factors in multiple stages of mammary cancer. The emphasis was on the SR family of splicing factors known to influence alternative splicing in a wide variety of genes, and on alternative splicing of the pre-mRNA encoding CD44, for which alternative splicing has been implicated as important in a number of human cancers, including breast cancer. We observed step-wise increases in expression of individual SR proteins and alternative splicing of CD44 mRNA during mammary gland tumorigenesis. Individual preneoplasias differed as to their expression patterns for SR proteins, often expressing only a sub-set of the family. In contrast, tumors demonstrated a complex pattern of SR expression. Little difference was observed between neoplasias and their metastases. Alternative splicing of CD44 also changed through the disease paradigm such that tumors produced RNA containing a mixture of variable exons, whereas preneoplasias exhibited a more restricted exon inclusion pattern. In contrast, other standard splicing factors changed little in either concentration or splicing pattern in the same cells. These data suggest alterations in relative concentrations of specific splicing factors during early preneoplasia that become more pronounced during tumor formation. Given the ability of SR proteins to affect alternative processing decisions, our results suggest that a number of pre-mRNAs may undergo changes in alternative splicing during the early and intermediate stages of mammary cancer.

This is a preview of subscription content, access via your institution

Access options

Buy this article

Prices may be subject to local taxes which are calculated during checkout

Figure 1
Figure 2
Figure 3
Figure 4
Figure 5

Similar content being viewed by others

References

  • Bell MV, Cowper AE, Lefranc MP, Bell JI and Screaton GR. . 1998 Mol. Cell. Biol. 18: 5930–5941.

  • Berget SM. . 1995 J. Biol. Chem. 270: 2411–2414.

  • Black DL. . 1995 RNA 1: 763–771.

  • Cáceres JF, Stamm S, Helfman DM and Krainer AR. . 1994 Science 265: 1706–1709.

  • Cáceres JF and Krainer AR. . (1997) In: Mammalian pre-mRNA splicing factors. Krainer AR (ed.).. IRL Press: Oxford pp.174–212.

    Google Scholar 

  • Cannistra S, Abu-Jawdeh G and Niloff J. . 1995 J. Clin. Oncol. 13: 1912–1921.

  • Cardiff RD. . 1988 Anticancer Res. 8: 925–933.

  • Chandler SD, Mayeda A, Yeakley JM, Krainer AR and Fu X-D. . 1997 Proc. Natl. Acad. Sci. USA 94: 3596–3601.

  • East JA and Hart IR. . 1993 Eur. J. Cancer 29A: 1921–1922.

  • Fox SB, Fawcett J, Jackson DG, Collins I, Gatter KC, Harris AL, Gearing A and Simmons D. . 1994 Cancer Res. 54: 4539–4546.

  • Friedrichs K, Kugler G, Franke F, Terpe HJ, Arlt J, Regidor PA and Gunthert U. . 1995 Lancet 345: 1237.

  • Fu X-D. . 1993 Nature 365: 82–85.

  • Fu X-D. . 1995 RNA 1: 663–680.

  • Ge H and Manley JL. . 1990 Cell 62: 25–34.

  • Ge H, Zuo P and Manley JL. . 1991 Cell 66: 373–382.

  • Gunthert U, Hoffmann M, Rudy W, Reber S, Zoller M, Haussmann I, Matzku S, Wenzel A, Ponta H and Herrlich P. . 1991 Cell 65: 13–24.

  • Gunthert U. . 1993 Curr. Microbiol. and Immunol. 184: 47–63.

  • Haynes BF, Hua-Xin L and Patton KL. . 1990 Cancer Cells 3: 347–350.

  • Heider KH, Mulder JW, Ostermann E, Susanni S, Patzelt E, Pals ST and Adolf GR. . 1995 Eur. J. Cancer 31A: 2385–2391.

  • Jerry DJ, Ozbun MA, Kittrell FS, Lane DP, Medina D and Butel JS. . 1993 Cancer Res. 53: 3374–3381.

  • Joensuu H, Klemi P, Toikkanen S and Jalkanen S. . 1993 Am. J. Path. 143: 867–874.

  • Kittrell FS, Oborn CJ and Medina D. . 1992 Cancer Res. 52: 1924–1932.

  • Krainer AR, Conway GC and Kozak D. . 1990a Genes Dev. 4: 1158–1171.

  • Krainer AR, Conway GC and Kozak D. . 1990b Cell 62: 35–42.

  • Kramer A. . 1996 Annu. Rev. Biochem. 65: 367–409.

  • Kaufmann M, Heider KH, Sinn HP, von Minckwitz G, Ponta H and Herrlich P. . 1995 Lancet 345: 615–619.

  • König H, Ponta H and Herrlich P. . 1998 EMBO J. 17: 2904–2913.

  • Lee MP and Feinberg AP. . 1997 Cancer Res. 57: 3131–3134.

  • Liu H-X, Zhang M and Krainer AR. . 1998 Genes Dev. 12: 1990–2012.

  • Mackay C, Terpe HJ, Stauder R, Marston WL, Stark H and Gunthert U. . 1994 J. Cell. Biol. 124: 71–82.

  • Manley J and Tacke R. . 1996 Genes Dev. 10: 1569–1579.

  • Medina D. . (1996) In: Mammary Tumor Cell Cycle, Differentiation and Metastases. Dickson RB and Lippman ME. (eds).. Academic Publishers: Norwell pp.37–69.

    Book  Google Scholar 

  • Moore MJ, Query CC and Sharp PA. . (1993) In: The RNA World. Gesteland RF and Atkins JF. (eds).. Cold Spring Harbor Laboratory Press: New York pp.303–357.

    Google Scholar 

  • Muller W, Schneiders A, Heider KH, Meier S, Hommel G and Gabbert HE. . 1997 J. Pathol. 183: 222–227.

  • Neugebauer KM and Roth M. . 1997 Genes Dev. 11: 1148–1159.

  • Norton PA. . 1994 J. Cell. Sci. 107: 1–7.

  • Reed R. . 1996 Curr. Opin. Genet. Dev. 6: 215–220.

  • Rio DC. . 1993 Curr. Opin. Genet. Dev. 3: 574–584.

  • Screaton GR, Bell MV, Jackson DG, Cornelis FB, Gerth U and Bell JI. . 1992 Proc. Natl. Acad. Sci. USA 89: 12160–12164.

  • Screaton GR, Cáceres JF, Mayeda A, Bell MV, Plebanski M, Jackson DG, Bell JI and Krainer AR. . 1995 EMBO J. 14: 4336–4349.

  • Silberstein GB, Van Horn K, Strickland P, Roberts Jr CT and Daniel CW. . 1997 Proc. Natl. Acad. Sci. USA 94: 8132–8137.

  • Sinn HP, Heider KH, Skroch-Angel P, von Minckwitz G, Kaufmann M, Herrlich P and Ponta P. . 1995 Breast Cancer Res. Treat. 36: 307–313.

  • Stamenkovic I, Amiot M, Pesando JM and Seed B. . 1989 Cell 56: 1057–1062.

  • Stickeler E, Runnebaum IB, Moebus VJ, Kieback DG and Kreienberg R. . 1997 Anticancer Res. 17: 1871–1876.

  • Sun Q, Mayeda A, Hampson RK, Krainer AR and Rottman FM. . 1993 Genes Dev. 7: 2598–2608.

  • Tran TA, Kallakury BV, Sheehan CE and Ross JS. . 1997 Hum. Pathol. 28: 809–814.

  • Valcarcel J and Green MR. . 1996 Trends Biochem. Sci. 21: 296–301.

  • Wang J and Manley JL. . 1995 RNA 1: 335–346.

  • Wielenga VJ, Heider KH, Offerhaus GJ, Adolf GR, van den Berg FM, Ponta H, Herrlick P and Pals ST. . 1993 Cancer Res. 53: 4754–4756.

  • Zamore PD, Patton JG and Green MR. . 1992 Nature 355: 609–614.

  • Zahler AM, Lane WS, Stolk JA and Roth MB. . 1992 Genes Dev. 6: 837–847.

  • Zahler AM, Neugebauer KM, Lane WS and Roth MB. . 1993a Science 260: 219–222.

  • Zahler AM, Neugebauer KM, Stolk JA and Roth MB. . 1993b Mol. Cell. Biol. 13: 4023–4028.

  • Zhu X, Daffada AA, Chan CM and Dowsett M. . 1997 Int. J. Cancer 72: 574–580.

Download references

Acknowledgements

This work was supported by Grant Sti 153/1-1 from the German Research Foundation (to E Stickeler), Grant DAMD 17-96-1-0684 from the US Army (to SM Berget) and Grant NCI CA 47112 from the National Cancer Institute (to D Medina).

Author information

Authors and Affiliations

Authors

Rights and permissions

Reprints and permissions

About this article

Cite this article

Stickeler, E., Kittrell, F., Medina, D. et al. Stage-specific changes in SR splicing factors and alternative splicing in mammary tumorigenesis. Oncogene 18, 3574–3582 (1999). https://doi.org/10.1038/sj.onc.1202671

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/sj.onc.1202671

Keywords

This article is cited by

Search

Quick links